Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 10/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497660 | 0.89 | CCR8 (0.56) | CCR8OPRM1KCNH2MGLLHCRTR1 | |
| SCHEMBL6497855 | 0.89 | CCR8 (0.56) | CCR8OPRM1KCNH2MGLLHCRTR1 | |
| SCHEMBL6500890 | 0.89 | CCR8 (0.56) | CCR8OPRM1KCNH2MGLLHCRTR1 | |
| SCHEMBL7068882 | 0.89 | CCR8 (0.56) | CCR8OPRM1KCNH2MGLLHCRTR1 | |
| SCHEMBL6507039 | 0.83 | CCR8 (0.56) | CCR8OPRM1KCNH2HTR7MGLL | |
| SCHEMBL6504157 | 0.78 | CCR8 (0.66) | CCR8KCNH2HTR7MGLLMEN1 | |
| SCHEMBL6496580 | 0.78 | CCR8 (0.56) | CCR8OPRM1KCNH2MGLLHCRTR1 | |
| SCHEMBL6500447 | 0.78 | CCR8 (0.47) | CCR8MGLLCHRM2CHRM3 | |
| SCHEMBL6508530 | 0.78 | CCR8 (0.47) | CCR8MGLLCHRM2CHRM3 | |
| SCHEMBL7158747 | 0.77 | CCR8 (0.53) | CCR8OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885OPRM1 494/4885KCNH2 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.